When the National Academy of Sciences and the National Academy of Medicine released a long-awaited report on human genome editing in February 2017, it was met with the media attention that befits a signal moment in science policy. Among a raft of measured recommendations, the report notes that heritable modifications to human DNA could be allowed in the future under strict regulatory oversight and solely for the purpose of treating serious diseases for which people have no recourse to reasonable alternatives (1). The result of year-long deliberations by an international committee of experts in science, law, and bioethics, the report's guidelines were largely unsurprising to many in the scientific community, given the intense scientific ferment in the field of genome editing and the handful of ongoing clinical trials involving nonheritable changes to the human genome. But some scholars strenuously objected to the recommendation on heritable genome editing, raising the specter of a future in which the fabric of society is unstitched by unequal access and genetic discrimination. Yet the report brims with cautionary language that counsels against the use of heritable editing except as a last resort, and only when such interventions are proven to be safe, when regulatory agencies are adequately equipped to oversee them, and when the tide of public opinion turns in their favor. Proving the need for such an abundance of caution, preliminary reports on editing mutations in viable human embryos grown in the laboratory suggest that the technique is far from ready for the clinic. PNAS asked Alta Charo, a professor of law and bioethics at the University of Wisconsin-Madison, who cochaired the committee behind the report, and George Church, a geneticist at Harvard Medical School, who works at the forefront of genome editing, to share their thoughts on the recommendations.
PNAS:
What were the committee's main considerations in deciding to "yellow-light," as it were, human germline editing?
Charo: The committee understood that germline genome editing was a sort of line in the sand, something we couldn't really cross in the past. The committee struggled to balance individual benefits against speculative societal risks. The primary benefit we considered was allowing people to have genetically related children without passing on serious diseases. In contrast to that, a lot of the concerns were speculative, such as possible effects on how tolerant we are of disabilities, possible effects on whether we view children as commodities or gifts, and possible effects of this intervention being extended to less-justifiable circumstances and lessserious diseases.
In the end, the recommendation we came out with lays down strict criteria from a regulatory standpoint about who may use germline genome editing in the absence of reasonable alternatives, for what kinds of conditions, and with what kind of oversight and follow-up for safety. The guts of that regulatory machinery are already in place, but it needs to be fully developed, as scientific research and public and policy discussions proceed alongside. Hopefully, in 5 to 10 years, all of these aspects-the scientific, regulatory, and sociopolitical-will have matured to the point where we can begin using the technique.
Church: It's a thoughtful and well-researched scientific report that recognizes the importance of public opinion.
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It strikes me as the sort of thing that is likely to have bipartisan support. Obviously, the report has its critics, but it is certainly cautiously worded. It will be interesting to see what impact the report is likely to have, particularly on the FDA's ability to review Investigational New Drug applications for human germline editing and on the NIH's ability to fund such research.
The report is peppered with caveats. What sort of conditions might meet these draconian criteria for human germline editing?
Church: Huntington's disease is often cited as an example, but in fact it can be addressed through alternative means, such as IVF [in vitro fertilization] and preimplantation genetic diagnosis. Admittedly, IVF is an expensive and invasive medical procedure that is not without potential issues (think hormone treatments), and people may have other ethical objections to it because it puts embryos at risk, in which case Huntington's would become a suitable candidate. But, depending on the geographic region, about 6-10% of people have severe recessive diseases, where both parents are carriers. For such people, germline gene editing might be a suitable option. The edits would be incorporated into the precursors of the gametes rather than the embryos and can be confirmed before the precursors are implanted. So, in effect, the safety issues tied to embryo editing can be mitigated.
Charo: Any genetic disorder that is highly penetrant and serious might be considered for germline editing. For example, Tay Sach's disease kills children at a young age and does not have a somatic therapy. Right now, couples have the option of either undergoing carrier screening and deciding not to have genetically related children or undergoing prenatal genetic testing. But if someone objects to discarding embryos after preimplantation genetic diagnosis or to aborting an affected fetus, then they really don't have any other options. Editing the gametes before the child is conceived would give them something that does not necessarily entail the loss of embryos or fetuses.
The report notes that rather than editing human gametes and embryos to prevent parents from passing on serious genetic diseases to children, one alternative might be to treat offspring born with the disease using nonheritable genome editing. Why not take that tack uniformly and skirt the ethical minefield of human germline editing?
Church: There are many examples of genetic diseases in which so much damage is done prenatally that somatic therapy [which involves editing human genes in a nonheritable fashion] would not help. Take some forms of microcephaly, for example. There is so much prenatal damage to brain tissue that even in utero somatic editing or postnatal editing may not be sufficient to restore function. That's where germline editing could help.
The report observes, somewhat ironically, that some people might consider the criteria so stringent as to amount to a virtual ban on human germline editing. Was that intended as a comforting thought to reassure potential critics?
Charo: We certainly didn't put in these stringent requirements so that people would conclude that they are never going to be met. We put them in because we thought these were reasonable prerequisites: limited application, long-term follow-up, and elaborate regulatory oversight. However, the requirements had the effect of some people saying that their concerns were allayed and others saying that they didn't believe any administrative agency could actually meet these criteria and go forth with germline editing.
On the other hand, some people might believe that the interpretation of the criteria may not be strict enough and that human germline editing applications beyond those recommended by the report will proceed anyway. I personally disagree with that viewpoint, but I do understand that there are people who take that position.
To ensure safety in the eventual use of human germline editing, the committee emphasized the need to follow offspring across generations. The logistical challenges of such long-term follow-up are legion, but are there comparable precedents for multigenerational follow-up in medicine?
Church: Most instances of multigenerational followup that I can think of tend to be ecological, but it is certainly conceivable in the medical realm. You could argue that the effects of thalidomide came to light through a second-generation follow-up; the mothers were exposed to the drug, and the children displayed the effects. PNAS: Perhaps the most logical critique leveled at the committee's recommendation on human germline editing relates to the distant but real possibility that genetic tinkering might be used to bestow advantages on the privileged, leading to an unequal society of genetic "haves" and "have-nots." Can you comment on the concern that permitting human germline editing might pave the road to personal enhancement and exacerbate disparities?
Charo: I think the question of enhancement is debatable. We accept many kinds of enhancement. Every time someone opts for, say, cosmetic surgery, they may be enhancing themselves in a way that has measurable effects on employability and prospects in the marriage market. The real concern is about global access to genetic enhancement, particularly against the backdrop of social inequity. So we carefully crafted the committee's views to say that for the moment the benefit of enhancement, if you are within the average range, is quite minimal, and the risks of the technology are real. So a simple risk-benefit analysis is not sufficient at the present time. But we do need public conversations about enhancement because the safety risks associated with the technology will go down. And when they do, we must ask whether even incremental enhancements justify the risks.
Church: Gene therapy, for instance, is often aimed at treating rare or orphan diseases, and for this reason it is often viewed as out of reach for most people. But when a technology is applied to common diseases, it tends to bring the price down. Another possibility that's worth discussing is that genome editing could lead to a more equal society. Take the smallpox vaccine as an analogy. There was a time when the wealthy were relatively spared because they were not exposed to the disease. With the advent of the smallpox vaccine, however, everyone was "enhanced," and the disease has been virtually eradicated. That's a kind of enhancement that could level the playing field for everyone in society. What we consider enhancement can also be relative to our ancestors, not just to one another.
The committee calls for public engagement in policymaking before clinical trials of genome editing for purposes other than disease prevention and treatment get underway. Does the report set down concrete steps for the same?
Charo: No, because that goes beyond the scope of the report. In fact, the Academy has published two other reports on modes of public engagement. That said, our report does have an appendix that lists examples from other countries, such as the parliamentary debates in the United Kingdom and the population polling and focus groups in France. We also point out longstanding examples in the United States where public commenting is possible, such as the public comments on agency rules and guidelines, the presidential commission on bioethics, and the NIH committee on recombinant DNA for specific protocols.
